<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515190</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-07-265</org_study_id>
    <secondary_id>82-31-920-1609</secondary_id>
    <nct_id>NCT00515190</nct_id>
  </id_info>
  <brief_title>Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma</brief_title>
  <official_title>A Randomized Phase II Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized phase II study designed to evaluate the efficacy and safety of continuous S-1 plus&#xD;
      oxaliplatin versus intermittent S-1 plus oxaliplatin as first-line therapy in patients with&#xD;
      recurrent and/or metastastic gastric carcinoma. Within 2 weeks of the end of induction&#xD;
      chemotherapy of 6 cycles with S-1 plus oxalipatin, patients who don't experience progression&#xD;
      will be randomized to the continuous S-1 plus oxaliplatin arm or the intermittent S-1 plus&#xD;
      oxaliplatin arm in a 1:1 ratio.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survial in the two treatment arms</measure>
    <time_frame>During study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate, toxicity, duration of response, time to progression, Quality of life in the two treatment arms,the effect of CYP2A6 genetic polymorphisms on the pharmacokinetics, treatment efficacy and toxicity</measure>
    <time_frame>During study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(continuous):S-1 plus oxalipatin will be continued until disease progression, unacceptable toxicity or consent withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(intermittent arm): Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1,oxaliplatin</intervention_name>
    <description>Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.&#xD;
Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed gastric adenocarcinoma with recurrent and/or&#xD;
             metastatic disease&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          4. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) or non-measurable evaluable&#xD;
&#xD;
          5. No prior treatment for recurrent and/or metastatic disease (prior adjuvant/neoadjuvant&#xD;
             therapy is allowed if at least 6 months has elapsed between completion of&#xD;
             adjuvant/neoadjuvant therapy and enrolment into the study; prior oxaliplatin is not&#xD;
             allowed)&#xD;
&#xD;
          6. Adequate major organ function including the following: Hematopoietic function: ANC &gt;=&#xD;
             1,500/mm3, Platelet &gt;= 100,000/mm3, Hepatic function: serum bilirubin =&lt; 1.5 x ULN,&#xD;
             AST/ALT levels =&lt; 2.5 x ULN (=&lt; 5 x ULN if liver metastases are present)Renal&#xD;
             function: serum creatinine =&lt; 1.5 x ULN&#xD;
&#xD;
          7. Patients should sign a written informed consent before study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lack of physical integrity of the upper gastrointestinal tract or malabsorption&#xD;
             syndrome (e.g. patients with partial or total gastrectomy can enter the study, but not&#xD;
             those with a jejunostomy probe), or inability to take oral medication&#xD;
&#xD;
          2. Patients with active (significant or uncontrolled) gastrointestinal bleeding&#xD;
&#xD;
          3. Residual relevant toxicity resulting from previous therapy (with the exception of&#xD;
             alopecia) ≥ grade 2 NCI-CTCAE version 3.0&#xD;
&#xD;
          4. Prior and/or current history of peripheral neuropathy&#xD;
&#xD;
               -  grade 1 NCI-CTCAE version 3.0&#xD;
&#xD;
          5. Inadequate cardiovascular function:New York Heart Association class III or IV heart&#xD;
             diseaseUnstable angina or myocardial infarction within the past 6 monthsHistory of&#xD;
             significant ventricular arrhythmia requiring medication with antiarrhythmics or&#xD;
             significant conduction system abnormality&#xD;
&#xD;
          6. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose&#xD;
             control may be jeopardized by complications of study therapy&#xD;
&#xD;
          7. Other malignancy within the past 3 years except non-melanomatous skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          8. History of or current brain metastases&#xD;
&#xD;
          9. Psychiatric disorder that would preclude compliance&#xD;
&#xD;
         10. Females with a positive or no pregnancy test (within 7 days before treatment start)&#xD;
             until childbearing potential can be otherwise excluded (postmenopausal i.e.&#xD;
             amenorrheic for at least 2 years, hysterectomy or oophorectomy)&#xD;
&#xD;
         11. Subjects with reproductive potential not willing to use an effective method of&#xD;
             contraception&#xD;
&#xD;
         12. Lactating women&#xD;
&#xD;
         13. Known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
         14. Patients receiving a concomitant treatment with drugs interacting with S-1 such as&#xD;
             flucytosine, phenytoin, or warfarin et al.&#xD;
&#xD;
         15. Major surgery within 4 weeks of start of study treatment, without complete recovery&#xD;
&#xD;
         16. Radiotherapy within 4 weeks of start of study treatment; 2 weeks interval allowed if&#xD;
             palliative radiotherapy was given to bone metastatic site and patient recovered from&#xD;
             any acute toxicity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sook Ryun Park, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sook Ryun Park, M.D.</last_name>
    <phone>+82-31-920-1609</phone>
    <email>sukryun73@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Se Youn Jang, M.S.</last_name>
    <phone>+82-+31-920-0667</phone>
    <email>jj96smc@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sook Ryun Park, M.D.</last_name>
      <phone>+82-31-920-1609</phone>
      <email>sukryun73@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Se Youn Jang, M.S.</last_name>
      <phone>+82-31-920-0667</phone>
      <email>jj96smc@naver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Neo Kyenong Kim, M.D.Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Iee Park, M,D.Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong Seok Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung-Ho Nam, M.D.Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young-Ho Yun, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>August 10, 2007</study_first_submitted>
  <study_first_submitted_qc>August 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2007</study_first_posted>
  <last_update_submitted>December 21, 2007</last_update_submitted>
  <last_update_submitted_qc>December 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Sook Ryun Park, M.D.</name_title>
    <organization>National Cancer Center, Korea</organization>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>Secondary</keyword>
  <keyword>Combination chemotherapy</keyword>
  <keyword>S-1</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

